How to Help Your Patients Save Money on Gynazole-1: A Provider's Guide to Savings Programs

Gynazole-1 (butoconazole nitrate 2% vaginal cream) is an effective single-dose treatment for vulvovaginal candidiasis, but its retail price of $165–$169 per applicator presents a significant cost barrier for many patients — particularly those without insurance or with plans that do not cover it. As a prescriber, you can play a direct role in reducing this burden by counseling patients about available savings programs at the point of prescribing. This guide covers everything you need to know.

Why Gynazole-1 Costs So Much

Gynazole-1 has no FDA-approved generic equivalent as of 2026. It is manufactured solely by Padagis (formerly Perrigo) and sold as a brand-name-only product. Without generic competition to drive down prices, Gynazole-1's retail cost remains elevated relative to OTC alternatives. Insurance coverage is inconsistent — some commercial plans cover it, but coverage under Medicare Part D is generally not available.

When patients face a $165+ out-of-pocket cost at the pharmacy, they often abandon the prescription in favor of OTC antifungals. While OTC options are effective for most uncomplicated VVC, this may not be ideal for all patients — and it represents a failure of the prescribing process to connect patients with cost-reduction tools they are entitled to use.

Savings Option 1: Padagis Gynazole-1 Patient Savings Program (Best for Most Patients)

The manufacturer's savings program is the most powerful cost-reduction tool for your patients:

Program name: Gynazole-1 Patient Savings Program

Provider: Padagis

Website: gynazole.com

Phone: 1-844-492-9820

Benefits:

• Commercially insured patients: pay as little as $25 per prescription (maximum savings of $70 per fill)
• Cash-paying patients: save up to $70 per prescription
• Insurance not required to participate (though savings may vary)
• No restrictions on number of uses; no expiration date listed
• How to get it: Patient downloads and prints the savings card from gynazole.com, then presents it at the pharmacy

Exclusions: Not available for patients using government-funded insurance programs (Medicare, Medicaid, TRICARE, or VA). Cash-paying patients without commercial insurance may pay more than insured patients.

Savings Option 2: GoodRx Coupon

GoodRx has negotiated a discount for Gynazole-1 in partnership with InsideRx and Perrigo, bringing the price to as low as $94.33 — approximately 44% off the retail price of ~$168.86 for the most common version. GoodRx is appropriate for patients who are uninsured, whose insurance doesn't cover Gynazole-1, or who prefer not to use insurance for this purchase.

Importantly, GoodRx pricing varies by pharmacy and location. Encourage patients to check GoodRx for the best price in their specific area before filling. Advise patients that GoodRx coupons are used instead of insurance — they cannot be combined with insurance billing.

Savings Option 3: SingleCare

SingleCare offers Gynazole-1 discounts that can bring the price to approximately $112.19 per applicator. As with GoodRx, SingleCare is used at the pharmacy in place of insurance. Patients can access the SingleCare card at singlecare.com or through their app.

Insurance Coverage Considerations

Coverage for Gynazole-1 varies widely by plan:

• Commercial insurance: Some plans cover Gynazole-1; others may require prior authorization or step therapy (requiring documented failure of an OTC option first). If a prior authorization is denied, consider the Padagis savings card as a next step.
• Medicare: Generally does not cover Gynazole-1. Medicare patients should be directed to GoodRx or the Padagis savings program (note: manufacturer copay cards cannot be used with Medicare).
• Medicaid: Coverage varies by state formulary. Patients may face prior authorization requirements or therapeutic substitution to an available generic antifungal.

Prior Authorization Support

If a patient's insurance requires prior authorization for Gynazole-1, the clinical rationale typically centers on documented failure of OTC antifungal treatment or a specific clinical reason for preferring single-dose prescription treatment (e.g., medication adherence concerns, recurrent VVC requiring prescription strength, or documented OTC failure). Most practices can support a prior authorization with appropriate chart documentation.

Integrating Cost Counseling Into the Prescribing Workflow

Best practice recommendation: At the time of prescribing Gynazole-1, provide patients with a brief verbal or written note pointing them to:

1. gynazole.com for the Padagis savings card (best option for commercially insured patients)
2. GoodRx.com to compare pharmacy prices and print a discount coupon
3. medfinder.com to help locate a pharmacy with it in stock (since price and availability are both issues for this medication)

This takes less than 60 seconds to communicate and can prevent prescription abandonment, a follow-up call from the patient, and the downstream cost of untreated infection.

When to Consider a Therapeutic Alternative for Cost Reasons

If savings programs still leave Gynazole-1 unaffordable for a patient — particularly uninsured patients or those on government programs — consider:

• Fluconazole 150 mg oral: Generic available for $5–$20 with GoodRx; requires prescription (avoid in pregnancy)
• Terconazole vaginal cream: Generic available, typically $30–$80 with coupon; requires prescription
• OTC miconazole or clotrimazole: $10–$25 OTC; clinically equivalent for uncomplicated VVC in most non-pregnant patients

Bottom Line for Providers

The Padagis savings program at gynazole.com is the single best cost-reduction tool for commercially insured patients, bringing the cost to as low as $25. For uninsured patients or those on government programs, GoodRx ($94+) is the next best option. Integrating cost counseling into your Gynazole-1 prescribing workflow takes seconds and dramatically reduces prescription abandonment. For broader guidance on supporting patients through Gynazole-1 availability challenges, visit medfinder for providers and see our clinical overview of Gynazole-1 availability for prescribers.